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4262 | Nanoscale, 2013, 5, 4262–426Controlled release of human growth hormone fused
with a human hybrid Fc fragment through a
nanoporous polymer membrane†
Eung-Sam Kim,‡a Do Soo Jang,b Seung Yun Yang,c Mi Nam Lee,d Kyeong Sik Jin,e
Hyung Jin Cha,d Jin Kon Kim,c Young Chul Sungbd and Kwan Yong Choi*ad
Nanotechnology has been applied to the development of more eﬀective and compatible drug delivery
systems for therapeutic proteins. Human growth hormone (hGH) was fused with a hybrid Fc fragment
containing partial Fc domains of human IgD and IgG4 to produce a long-acting fusion protein. The
fusion protein, hGH-hyFc, resulted in the increase of the hydrodynamic diameter (ca. 11 nm) compared
with the diameter (ca. 5 nm) of the recombinant hGH. A diblock copolymer membrane with nanopores
(average diameter of 14.3 nm) exhibited a constant release rate of hGH-hyFc. The hGH-hyFc protein
released in a controlled manner for one month was found to trigger the phosphorylation of Janus
kinase 2 (JAK2) in human B lymphocyte and to exhibit an almost identical circular dichroism spectrum
to that of the original hGH-hyFc, suggesting that the released fusion protein should maintain the
functional and structural integrity of hGH. Thus, the nanoporous release device could be a potential
delivery system for the long-term controlled release of therapeutic proteins fused with the hybrid Fc
fragment.Introduction
Human growth hormone (hGH) is a single-chain polypeptide
with 191 amino acids secreted by the pituitary gland. For the
treatment of poor growth and AIDS-associated wasting
syndrome in children1,2 and adults,3–5 respectively, the
recombinant hGH (rhGH) has been approved and administrated
in the injectable formulation via subcutaneous or intramuscular
routes. Since its short circulating half-life (20 to 30 min)
requiredmultiple injections for patients,6,7 it is expected that the
long-term controlled release formulation for the long-acting
hGH will be desirable and improve the patients' compliance.d Bioengineering, Pohang University of
ng, Korea. E-mail: kchoi@postech.ac.kr;
, Korea
hemical Engineering, POSTECH, Pohang,
cular Life Sciences, Division of Integrative
ohang, Korea
Pohang, Korea
(ESI) available: Structural features of
A for hgH-hyFc quantication, other
stability of hGH-hyFc, assembly of a
rat IgG antibody, release proles of
M images of nanoporous membranes
See DOI: 10.1039/c3nr00474k
Consortium (SBIC), 11 Biopolis Way
7.
9For the sustained release of hGH, various depot systems such
as microparticles,8,9 liposomes,10 hydrogels6,11 and implants12
have been developed. The natural or synthetic polymer like
hyaluronic acid and poly-lactic glycolic acid could also encapsu-
late the therapeutic protein into microspheres.13,14 The polymer-
based depot systems have to overcome the possibility of dena-
turation of proteins due to the formulation in organic solvents or
acidic environment even though the biodegradable polymers
were compatible to the human body. The conformational
stability of rhGH in the depot system is an essential determinant
to maintain its biological activity and to minimize undesired
immunogenicity, since the active form of hGH has a four-helix
architecture.15 The aggregation of rhGH resulted in lower eﬃcacy
than its native monomeric form.16,17 Thus, the solvent-free envi-
ronment during formulation and storage would enhance the
therapeutic outcome in the sustained release system for rhGH.
In order to extend the half-life of therapeutic proteins in the
blood stream, they were genetically fused to the stabilizing
peptide,17 albumin or scaﬀold18 of antibody heavy chains19
without any other modication such as PEGylation or glycosyla-
tion, thereby improving their pharmacokinetic properties. As
many strategies to enhance the serum-half life of therapeutic
proteins have been implemented, more eﬀective delivery systems
are still needed to maximize their eﬃcacy by controlling the
release prole. We recently devised a strategy to extend the serum
half-life by constructing a exible hybrid Fc with partial regions
of IgG4 and IgD and then fusing it with erythropoietin (EPO).20
IgG4 exhibited weaker binding aﬃnity with Fcg receptors orThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinecomplement component 1q than IgG1, the most widely used
human Fc molecules.21 The IgG4 Fc could circumvent antibody-
dependent cellular cytotoxicity or complement-dependent cyto-
toxicity.22 Additionally, the IgD fragment region of the hybrid Fc
contributed the exibility of the EPO-conjugate.20
The recent advancements of nanotechnology have enabled
many nanoporous systems made of polymer or silica to over-
come the challenging hurdles in separation and delivery of
biomolecules.23 Owing to the tunability of pore size, the nano-
porous membrane derived from block copolymers has been
exploited in the size-exclusive diﬀusion of target molecules and
ultraltration.24 Among the synthetic nanoporous membranes,
a thin lm of block copolymers such as polystyrene-block-poly-
methylmethacrylate (PS-b-PMMA) having hexagonally packed
nanochannels vertically oriented to the membrane surface was
reproducibly prepared by our group for the ltration of viral
particles, controlled release of therapeutic proteins, and
detection of single-base mismatch in DNA.25–28
Here, we attempted to control the release rate of hGH fused
with a hybrid Fc fragment of human antibody, hGH-hyFc, as
schematically shown in Fig. 1(a), using the nanoporousFig. 1 Comparison of molecular sizes of rhGH, hGH-hyFc, and rat IgG by gel electrop
hGH-hyFc: hGH (in red) is fused to the hybrid human Fc which consists of the hinge
IgG4 (in yellow). The disulﬁde bond (in black) between cysteine residues in the indiv
three proteins were respectively run on a 6–16% gradient polyacrylamide gel with
gradient gel containing 2 ng of each protein was transferred to the nitrocellulose m
mouse and anti-rat HRP-conjugated antibodies as a primary and secondary antibo
measured by dynamic light scattering using a 40 ml cuvette. The peaks representing th
hGH-hyFc (2), and IgG antibody (3), respectively.
This journal is ª The Royal Society of Chemistry 2013copolymer membrane fabricated with PS-b-PMMA. As in the
EPO-hyFc,20 the upper part of the hybrid Fc of hGH-hyFc is from
human IgD Fc, and its lower part is from human IgG4 Fc. The
molecular size of hGH-hyFc was characterized by gel electro-
phoresis, dynamic light scattering, electron microscopy, and
small-angle X-ray scattering. The diameter of ordered nano-
pores in the polymer membrane was adjusted to the hydrody-
namic diameter of hGH-hyFc. The release prole of hGH-hyFc
through the nanoporous polymer membrane for onemonth was
quantitatively analyzed. The biological function of the released
hGH-hyFc was also investigated in a human B cell line, IM-9.
The release of hGH with a human hybrid Fc was found to be
controlled by the nanoporous membrane which could be
applied to the delivery system of therapeutic proteins with a
constant release rate for a long period.Experimental
Proteins and chemicals
Puried hGH-hyFc which was expressed in Chinese hamster
ovary cells (CHO-DG44) was provided by Genexine, Inc. (Seoul,horesis, immunoblotting and dynamic light scattering. (a) Schematic structure of a
region of the human IgD (in green) and the major CH2/CH3 domain of the human
idual hinge region of IgD induces the dimeric formation of hGH-hyFc. (b) 2 mg of
the non-reducing loading buﬀer and stained with Coomassie Blue solution. The
embrane for western blotting using anti-hGH antibody and the mixture of anti-
dy, respectively. (c) The hydrodynamic diameters of three proteins in PBS were
emean hydrodynamic diameter were observed at 4.8, 10.5, and 13.3 for rhGH (1),
Nanoscale, 2013, 5, 4262–4269 | 4263
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View Article OnlineKorea). The puried hGH-hyFc was stored at 4 C in a storage
buﬀer (50 mM sodium phosphate, 15 mM NaCl, pH 6.8 at
25 C). The monoclonal rat anti-mouse IL-2 IgG2a antibody and
non-glycosylated recombinant human growth hormone (rhGH)
were obtained from BioLegend (San Diego, CA, USA) and Cell
Sciences (Canton, MA, USA), respectively. All chemicals and
solvents of reagent grade were purchased from Sigma-Aldrich
(St. Louis, MO, USA), unless otherwise mentioned. All reagents
were used without further purication. Ultra-pure water (18.2 
106U cm) for the preparation of aqueous solutions was supplied
by a Milli-Q purication system (Millipore).
Immunoblotting
The rhGH, hGH-hyFc, and IgG2a (Table S1 in the ESI†) were
separated in a 6–16% gradient SDS-polyacrylamide gel and
transferred to a nitrocellulose membrane. The membrane was
blocked by 4% (w/v) skimmedmilk in a transfer buﬀer and then
probed sequentially by an anti-hGH antibody (Santa Cruz) as a
primary antibody and a horseradish peroxidase (HRP)-conju-
gated secondary antibody mixture containing goat anti-mouse
and anti-rat IgGs (Zymed). The chemo-luminescence from the
enzymatic reaction of peroxidase in the presence of an
enhanced chemiluminescence solution (Thermo, Rockford, IL,
USA) was detected by an X-ray lm (Agfa, Belgium).
Photon correlation spectroscopy
The hydrodynamic diameters of rhGH, hGH-hyFc, and IgG
antibody were determined by dynamic light scattering (DLS)
using a Zetasizer Nano S (Malvern Instruments, UK). The
proteins with a concentration of 1 mg ml1 in 1 phosphate
buﬀered saline solution (PBS, pH 7.4 at 25 C) were loaded into
a low-volume (40 ml) quartz cuvette. The distribution of protein
size was statistically represented by mean and standard devia-
tion of three independent measurements. A single measure-
ment consisted of thirty readings for scattering signals.
Transmission electron microscopy
hGH-hyFc (1 mg ml1) solution was desalted in a dialysis tube
(D-tube, EMD Chemicals) for 6 h at room temperature and then
mounted on a copper grid. The copper grid was dipped into the
uranyl acetate (0.5 to 2%) for 2 s and dried in air. Electron
micrographs were recorded at 500 000 magnication on a
transmission electron microscope (JEM-1011, JEOL) at 80 kV.
Small angle X-ray scattering (SAXS)
X-ray scattering was carried out at the solution-scattering
station set up at the 4C1 and 4C2 beam line at the Pohang
Accelerator Laboratory (Pohang, Korea). The volume and path
length of the sample cell were 50 ml and 1 mm, respectively. All
measurements were performed at 25 C. The intensity of X-ray
scattering in the small angle region was determined according
to the equation reported previously:29 I(Q) ¼ I(0)exp(Rg2Q2/3),
where Q and I(0) are the momentum transfer and intensity at 0,
respectively; Q was dened by Q ¼ 4psin q/l, where 2q and l are
the angle between the incident X-ray beam and the detector4264 | Nanoscale, 2013, 5, 4262–4269measuring the scattered intensity and wavelength of X-ray,
respectively. The radius of gyration (Rg) was obtained from the
slope of the Guinier plot (ln I(Q) versus Q2).
Titanium reservoir with a nanoporous polymer membrane
The nanoporous block copolymer membrane was fabricated as
described previously.27 Briey, the mixture of PS-b-PMMA and
PMMA homopolymer in toluene was spin-coated on the silicon
oxide layer of the silicon wafer and thermally annealed. To
separate the polymer lm from the wafer surface, the oxide layer
was dissolved in the HF solution. The lm was placed on the
supporting membrane and was subjected to the generation of
cylindrical nanopores by removing the PMMA homopolymer in
the cylindrical PMMA block and swelling the PMMA block with
acetic acid. The nanoporous membrane was dried under
vacuum. The surface of the nanoporous polymer membrane
was imaged using a eld-emission scanning electron micro-
scope (FE-SEM, Hitachi S-4600, Japan). For the titanium
reservoir, its lower part wasmachined to have an inner diameter
of 15 mm and a depth of 5 mm. The outer surface of the lower
part and the inner surface of the cover were screwed to fasten
each other.
Detection of released proteins
The original solution of 1 mg ml1 IgG was diluted in sterilized
PBS to the concentration of 500 mg ml1. The hGH-hyFc which
was supplemented with 1 mg ml1 bovine serum albumin (BSA)
for its stable long-term storage was diluted to 9000 ngml1. The
protein solution was transferred to the lower part of the tita-
nium reservoir. Prior to capping the cover, the circular
membrane assembly of the supporting layer and the nano-
porous polymer lm was soaked in ethanol and deionized water
sequentially. The wet membrane assembly was placed on the
lower part of the titanium reservoir and the cover with a central
hole was screwed. The titanium reservoir was immersed in a
glass vessel containing PBS containing 0.1% BSA and the
released protein was sampled at diﬀerent time points. The
sampled IgG antibodies were run on an 8% sodium dodecyl
sulfate (SDS)-polyacrylamide gel and visualized by a silver
staining kit (GE Healthcare). The released hGH-hyFc proteins
that were sampled at diﬀerent time points were run on an 8%
SDS-polyacrylamide gel and visualized by immunoblotting with
anti-hGH antibody (Santa Cruz) as a primary antibody and HRP-
conjugated goat anti-mouse IgG antibody (Zymed) as a
secondary antibody.
Enzyme-linked immunosorbent assay (ELISA) for hGH-hyFc
For a sandwich-type ELISA (Fig. S1 in the ESI†), the anti-hGH
antibody raised in a goat was diluted in PBS to the nal
concentration of 5 mg ml1. 60 ml of diluted antibody was
incubated in each well of 8-well strips (Costar EIA/RIA strip,
Corning) for 24 h at 4 C followed by washing the wells with PBS
containing 0.5% (v/v) Tween 20, PBST, three times to remove the
unbound capture antibody. The well surface was blocked with
200 ml of 1% (w/v) BSA (Fraction V, Roche) in PBS for 1 h at 25 C
and washed with PBST four times. The sampled solution for theThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinefusion protein was incubated in the well for 1.5 h at 25 C fol-
lowed by washing four times with PBST. The HRP-conjugated
anti-human IgG-Fc antibody (Bethyl Lab., TX, USA) as the
detection antibody was diluted in PBS supplemented with 0.5%
BSA to the nal concentration of 50 ng ml1. The detection
antibody was incubated in the well for 1.5 h at 25 C followed by
washing ve times with PBST. The chemo-luminescence signal
was developed by adding 100 ml of TMB solution (KPL, MD,
USA), stopped by adding 100 ml of 2.0 N H2SO4, and read at
450 nm in the 96-well plate reader (TECAN).Circular dichroism (CD) spectroscopy
CD spectra of hGH-hyFc were obtained using a spec-
tropolarimeter (J-715, JASCO) at 20 C under nitrogen. All scans
from 250 nm to 200 nm for each sample in a quartz cuvette with
2 mm path length were done in triplicate. Raw data were
acquired at 0.2 nm step size with 1 s response time. The residual
ellipticity was obtained as an average of three scans and con-
verted to molar ellipticity as described previously.30Immunoassay for detection of JAK2 phosphorylation in IM-9
cells
IM-9 cells obtained from the Korean Cell Line Bank (http://
cellbank.snu.ac.kr) were cultured in the RPMI-1640 medium
(GIBCO, USA) supplemented with 10% (v/v) fetal bovine serum
(FBS, Invitrogen, UK), 100 U mL1 penicillin G, and 100 mg
mL1 streptomycin at 5% CO2 and 37 C. Prior to treatment of
rhGH and hGH-hyFc, cells (2  106 cells per 1.5 ml in 6-well
plate) were resuspended in RPMI-1640 medium supplemented
with 0.5% FBS for 12 h. Each protein of 1000 ng was applied to
the cells and the treated cells were harvested at diﬀerent time
points by centrifugation. The cells were solubilized in a cell lysis
buﬀer containing 40 mM HEPES, pH 7.5, 0.5% Tx-100, 120 mM
NaCl, 1 mM EDTA, 10 mM pyrophosphate, 50 mM NaF, 1.5 mM
Na2VO3, 10 mM b-glycerophosphate, 1 mM phenyl-
methylsulfonyl uoride, 5 mM MgCl2, and the protease inhib-
itor cocktail (Roche). The cell lysates were centrifuged at 15 000g
for 30 min at 4 C and supernatants were recovered. The
phosphorylation of JAK2 was analyzed by SDS-PAGE and
immunoblotting using the anti-phospho-JAK2 (Tyr1007/1008)
antibody (Cell Signaling) and HRP-conjugated goat anti-rabbit
IgG antibody (Jackson ImmunoResearch Lab.) as a primary and
secondary antibody, respectively. The total amounts of JAK2 and
actin were also monitored by the western blotting using anti-
human JAK2 antibody (Cell Signaling) and anti-actin antibody
(Santa Cruz) for the normalization of phosphorylation of JAK2
and the loading control of the cell lysate, respectively. The
developed bands on the X-ray lm were quantied with the NIH
ImageJ program (available at http://rsbweb.nih.gov/ij/).Results and discussion
Characterization of hGH-hyFc fusion protein
The molecular weight and specic aﬃnity of hGH-hyFc were
compared with those of rhGH and rat IgG antibody by gel elec-
trophoresis and immunoblotting. The puried hGH-hyFc wasThis journal is ª The Royal Society of Chemistry 2013homogeneous as judged by a single band of a 130 kDa protein
upon the PAGE analysis, while rhGH and rat IgG were found to
be ca. 20 kDa and 170 kDa, respectively (Fig. 1(b)). When hGH-
hyFc was treated with dithiothreitol (DTT) to reduce the disulde
bond between two Fc scaﬀolds, monomeric hGH-hyFc of ca.
55 kDa could be separated (Fig. S2 in the ESI†). Both dimeric and
monomeric hGH-hyFc were found to have specic aﬃnity to anti-
human IgG and anti-hGH antibodies. The hydrodynamic diam-
eters of rhGH, hGH-hyFc and IgG antibody in PBS were 4.8 0.9,
10.5  2.1, and 13.3  4.3 nm (mean  SD), respectively, as
measured by dynamic light scattering (Fig. 1(c)). The overall
dimension of the dimeric hGH-hyFc was approximately 10 nm in
width and 12 nm in height as determined by transmission
electron microscopy (Fig. S2 in the ESI†). The radii of gyration
(Rg) of hGH-hyFc and rhGH were measured to be 4.69 
0.0187 nm and 2.08  0.0083 nm, respectively, by SAXS analysis.
Since hGH-hyFc is a fusion protein consisting of hGH and
partial Fc fragments from human IgD and IgG4, its homodi-
meric molecular weight based on the amino acid sequence
would be ca. 100 kDa. The glycosylation of hGH-hyFc in the
CHO cell could account for the increase in its molecular weight
as shown in the gel. The PNGase F treatment to cleave the bond
between GlcNAc and asparagine yielded 3 kDa-smaller mono-
meric hGH-hyFc compared to the native one (Fig. S2 in the
ESI†). As we previously explored the overall structure of EPO-
hyFc using SAXS,20 we also found that hGH-hyFc had a Y-shaped
structure (Jang et al., unpublished data). In addition, hGH-hyFc
could retain its molecular integrity for at least one month in the
culture medium for IM-9 cells as monitored by SDS-PAGE and
CD spectroscopy. The physical or structural transformation of
hGH-hyFc such as fragmentation, nonspecic adsorption,
dimerization or aggregation, which had been frequently
observed in rhGH,31–33 was not exhibited for 30 days (Fig. S3 in
the ESI†). The unchanged antigen specicity against the anti-
hGH antibody suggested that there should be no signicant loss
of activity as a ligand for its cellular receptors during this
period. Thus, the hGH fused with human hybrid Fc domains
was found to have the two-fold bigger hydrodynamic diameter
and six-fold larger molecular weight than the native rhGH,
retaining hGH activity and conformational stability under the
culture conditions for at least one month.Controlled release of hGH-hyFc via nanoporous membranes
Nanopores in the 80 nm thick polymer lm fabricated by a self-
assembling diblock copolymer, PS-b-PMMA, were found to be
arranged in a self-ordered format as shown in Fig. 2(a) and 2(b).
The diameter of nanopores and the center-to-center distance
between two neighboring nanopores were 14.3  2.5 and 36.2 
4.1 nm, respectively. The fraction of the area covered by nano-
pores on the surface of the polymer lm was calculated to ca.
15%. The titanium reservoir equipped with the nanoporous
polymer membrane (Fig. S4 in the ESI†) was employed to
control the release of hGH-hyFc to the aqueous solution. As a
control experiment, the rat IgG antibody with the initial
concentration of 500 mg ml1 was entrapped in the titanium
reservoir and immersed in the PBS solution. The released IgGNanoscale, 2013, 5, 4262–4269 | 4265
Fig. 2 Nanoporous diblock polymer membrane. (a) The schematic diagram for the nanoporous polymer membrane fabricated by the polystyrene-block-poly-
methylmethacrylate (PS-b-PMMA) copolymer. The cross-section of a cylinder-shaped nanochannel is represented in an enlarged schematic. The PMMA block was
swelled onto the PS block in acetic acid to generate cylindrical nanochannels. (b) SEM image of self-ordered nanopores in the polymer membrane with their porosity of
15%. The white-lined box was magniﬁed to show the hexagonal arrangement of nanopores with an average diameter of 14.3 nm and a center-to-center distance of
36.2 nm. The line in the inset represents a scale bar with 50 nm. (c) Percentage distribution of the diameters of nanopores. The diameter of each pore in three random
regions (1 mm  1 mm for each region) of the nanoporous membrane was measured.
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View Article Onlineantibody up to 14 days could be detected and quantied by
silver staining aer gel electrophoresis (Fig. S5 in the ESI†). The
rate of sustained release of IgG antibody was approximately
270 ng h1 as estimated by the slope of the regression line.
When hGH-hyFc at the initial concentration of 1800 ng ml1
or 9000 ng ml1 was released through cylindrical nanochannels
of the nanoporous polymer membrane, the amount of released
hGH-hyFc proteins was found to be proportional to the release
time as evidenced by immunoblotting (Fig. 3). The rates of hGH-
hyFc release were estimated to be 4.4 ng h1 and 22 ng h1 for
the initial concentrations of 1800 ng ml1 and 9000 ng ml1,
respectively. The constant release of hGH-hyFc was sustained
up to 25 days for the two diﬀerent initial concentrations. The
diﬀerence between the CD spectrum of hGH-hyFc released aer
25 days and that of initial hGH-hyFc was negligible, suggesting
that little conformational change was made along the
controlled release. When the average diameter of nanopores
was 27 nm, the release rate was not constant over the 25 day
long release (Fig. S6 in the ESI†). Additionally the small nano-
pore with 7.4 nm in average diameter could hardly release hGH-
hyFc so that the total amount of released hGH-hyFc for 25 days
was 43-fold less than that of hGH-hyFc released through 14 nm
diameter nanopores.
The constant release of hGH-hyFc without initial burst
prole was achieved by the nanoporous polymer membrane4266 | Nanoscale, 2013, 5, 4262–4269with uniform diameter of nanopores. Since the ratio of the
hydrodynamic diameter of hGH-hyFc to the average diameter of
the nanopore was ca. 73%, the diﬀusion-driven release of the
fusion protein could be modeled to the single-le diﬀusion as
described previously34 to explain the constant release of parti-
cles through the channel whose diameter is not two-fold larger
than that of the particle. The gold deposition to the nanoporous
polymer membrane was introduced to reduce the eﬀective
diameter of the nanopore to 6 nm, resulting in the constant
release prole of rhGH27 whose hydrodynamic diameter was ca.
4 nm,33 whereas the Fickian diﬀusion prole35 was observed in
the bare nanoporous membrane with no gold deposition. The
constant rate of controlled release of hGH-hyFc was dependent
on the initial concentration in the reservoir. The rate of four-
week-long release was found to be proportional to the initial
reservoir concentration. The spontaneous pore closing that
could be encountered in the poly(lactic-co-glycolic acid) micro-
sphere and hinder the controlled release of proteins36 was not
observed in our nanoporous membrane aer the one-month
release. Additionally, the 80 nm long nanochannel did not
cause any damage to hGH-hyFc, which might be accompanied
by its conformational denaturation with reduced functional
activity due to the random contact to the polymer surface
during the one-dimensional diﬀusion in the nanochannel. The
non-specic adsorption of the fusion protein on the surface ofThis journal is ª The Royal Society of Chemistry 2013
Fig. 3 Controlled release of hGH-hyFc through the nanoporous polymer membrane. (a) Schematic diagram for controlled release of hGH-hyFc passing through the
cylindrical nanochannels. (b) Western blotting for released hGH-hyFc up to 72 h with puriﬁed hGH-hyFc as a standard for quantiﬁcation. The initial concentration of
hGH-hyFc in the titanium reservoir was set at either 1800 ng ml1 or 9000 ng ml1. Quantiﬁcation of released hGH-hyFc at diﬀerent time points to estimate the release
rate from the three independent experiments: (c) release proﬁle from 0 h to 80 h and (d) release proﬁle from 0 days to 25 days. (e) Comparison of CD spectra of hGH-
hyFc before and after the 25 day long release.
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View Article Onlinethe nanoporous lm or the supporting layer was negligible as
judged by SEM images (Fig. S7 in the ESI†). Therefore, we
demonstrated the controlled release of functionally active hGH-
hyFc with an average hydrodynamic diameter of 11 nm through
the polymer membrane with 14 nm nanopores.Signaling of released hGH-hyFc in human B cells
The biological function of hGH-hyFc on human B cells was
examined by the detection of phosphorylated-JAK2 (p-JAK2),
since JAK2 was known to be a growth hormone receptor-associ-
ated tyrosine kinase.37 Like rhGH, when hGH-hyFc was bound toThis journal is ª The Royal Society of Chemistry 2013the receptor on IM-9 cells, it could induce the phosphorylation of
JAK2 (Fig. 4). The highest p-JAK2 level was observed at 5min aer
the treatment of hGH-hyFc and rhGH, respectively. The p-JAK2
level was attenuated to the basal level at 60 min aer the treat-
ment. The amount of unbound hGH-hyFc proteins in the culture
medium was assessed by ELISA aer the removal of suspended
cells by centrifugation. The initial concentration (800 ng ml1) of
hGH-hyFc was decreased to 250 ngml1 at 5 min in the presence
of IM-9 cells and marginally decreased to 200 ng ml1 up to 480
min whereas the protein level remained constant up to 480 min
in the absence of cells. The concentration of free hGH-hyFc
molecules in the culture medium was abruptly reduced withinNanoscale, 2013, 5, 4262–4269 | 4267
Fig. 4 Phosphorylation of JAK2 upon the treatment of IM-9 cells with rhGH and
hGH-hyFc. (a) Levels of phosphorylated-JAK2 (p-JAK2) upon the treatment of IM-
9 cells with hGH-hyFc or hGH at the ﬁnal concentration of 670 ng m1. b-actin
was used as a loading control. (b) Change of p-JAK2 levels normalized by JAK2
levels as a function of treatment time. The error bar represents the standard
deviation from the three independent experiments.
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View Article Online5 min and no more signicant change in the concentration of
unbound hGH-hyFc molecules was observed aer 5 min. No
fragmentation of the fusion protein was observed as judged by
the immunoblotting analysis of hGH-hyFc. When IM-9 cells were
treated with hGH-hyFc at diﬀerent doses from 16 to 4000 ng
ml1, the peak of tyrosine phosphorylation levels of JAK2 reached
at 1000 ngml1 within 5min of stimulation. The p-JAK2 level wasFig. 5 Phosphorylation of JAK2 of IM-9 cells in response to released hGH-hyFc. (a) C
hyFc. (b) Quantiﬁcation of p-JAK2 levels normalized by the JAK2 level. (c) Phosphoryla
the hGH-hyFc released through the nanoporous membrane for 5, 15, and 25 days,
4268 | Nanoscale, 2013, 5, 4262–4269decreased in the treatment of hGH-hyFc at the concentration
higher than 2000 ng ml1 (Fig. 5(a) and (b)). The hGH-hyFc that
underwent the controlled release through the nanoporous
membrane triggered the phosphorylation of JAK2, when the cells
were suspended in the culture medium containing hGH-hyFc
that was released for 25 days. The p-JAK2 level reached the peak
in the 15 day long release medium and went down in the 25 day
long release medium (Fig. 5(c) and (d)).
The homodimerization of hGH receptors is initiated by the
interaction of hGH having two binding sites that are responsible
for the engagement with a cell-surface receptor. The hGH-
mediated receptor dimerization is required for the tyrosine
phosphorylation of JAK2 that is associated with each hGH
receptor. The kinetic analysis of the JAK2 phosphorylation in
response to the single treatment of rhGH and hGH-hyFc revealed
that its rapid activation could peak within 5 min and be followed
by the slow decrease to the deactivated state at 120 min. When
the number of hGH ligands supposed to participate in the
receptor engagement was considered, the molar concentration
of hGH ligands in hGH-hyFc containing two hGHs per molecule
was 2.5-fold lower than that of rhGH under the same mass
concentration. The higher ratios of p-JAK2 level to JAK2 levels
supported the more eﬀective signaling function of hGH-hyFc
compared to that of rhGH. However, there seemed to be an
optimum concentration of hGH-hyFc in IM-9 cells to trigger the
tyrosine phosphorylation of JAK2 for a given number of cells.
The mathematical model could explain the bell-shaped cellular
response, showing an inhibitory eﬀect on the receptor dimer-
ization due to the high concentration hGH ligand.38 The
concentration of unbound hGH-hyFc was decreased by 72%
upon the treatment of IM-9 cells with hGH-hyFc while it was nothange in p-JAK2 levels after the single 5 minute treatment of IM-9 cells with hGH-
tion of JAK2 of IM-9 cells that were exposed for 5 min to the culture mediumwith
respectively. (d) Ratio of p-JAK2 to JAK2 levels in response to released hGH-hyFc.
This journal is ª The Royal Society of Chemistry 2013
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View Article Onlinein the absence of IM-9 cells up to 2 h, suggesting that hGH-hyFc
released through the nanoporousmembrane could activate IM-9
cells to induce the phosphorylation of JAK2 when the released
fusion protein was treated with the inactivated cell.Conclusions
We demonstrated the controlled release of hGH-hyFc, a long-
acting hGH using the nanoporous polymer membrane in a
titanium reservoir. The fusion of hGH with the hybrid antibody
Fc fragment originated from IgD and IgG4 was found to be
stable in the cell culture medium and hGH-hyFc was able to
activate JAK2 signaling more eﬀectively compared with the
recombinant hGH. The nanoporous polymer membrane made
of the diblock copolymer was proven to be an eﬃcient delivery
system of hGH-hyFc with a larger hydrodynamic diameter than
the unmodied hGH, exhibiting a constant release rate for at
least one month. The released hGH-hyFc showing conforma-
tional stability could trigger the cellular response. The
combined strategy to release the long-acting therapeutic protein
with a hybrid Fc through the nanoporous membrane has a
potential to be developed into a long-term drug delivery system.Acknowledgements
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